Dedicated Breast Radiotherapy System
Breast Cancer
CommercialActive
Key Facts
About Ehmet Health
Ehmet Health is an emerging innovator in the radiopharmaceuticals and medical device sector, focusing on making advanced radiotherapy more accessible and efficient. The company's technology portfolio centers on two main platforms: a scalable, synchrotron-based proton therapy system (KODA ONE) and a specialized, self-shielded breast radiotherapy system. By emphasizing modular design, unified software, and patient-centric solutions, Ehmet aims to lower the cost and complexity barriers associated with high-precision radiation therapy, targeting a significant global market need. The company is privately held and appears to be in a pre-revenue or early commercial stage as it deploys its initial systems.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |